Copyright
©The Author(s) 2025.
World J Diabetes. May 15, 2025; 16(5): 104787
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.104787
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.104787
Table 1 Various categories of monogenic diabetes with genes involved in the pathogenesis and the clinical features, with special emphasis on monogenic diabetes other than maturity-onset diabetes of the young and neonatal diabetes mellitus
Types | Subtypes/varieties | Gene/protein | Clinical features | Inheritance |
MODY | MODY 1 to 14 | See Table 2 | See Table 2 | |
Neonatal diabetes | Permanent NDM | See Table 2 | See Table 2 | |
Transient NDM | See Table 2 | See Table 2 | ||
Other monogenic diabetes with defective insulin synthesis and secretion | Mitochondrial DM | m.3243A > G | Maternally inherited diabetes and deafness | Maternal |
Wolfram syndrome 1 or 2 | WFS1 or CISD2 | DIDMOAD 1 or 2 diabetes insipidus, diabetes mellitus, optic atrophy and deafness | AR | |
Rogers syndrome | SLC19A2 | Thiamine-responsive megaloblastic anaemia, deafness, and diabetes | AR | |
H or PHID syndrome | SLC29A3 | H syndrome: Hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomaly, hearing loss, low height, hypogonadism and hyperglycaemia; PHID syndrome | AR | |
Monogenic autoimmune diabetes syndromes | IPEX syndrome | FOXP3 | IPEX syndrome | XR |
LRBA | Common variable immunodeficiency 8 | AR | ||
STAT3 | Infancy-onset multi-system autoimmune disease type 1 | AD | ||
APECED syndrome | AIRE | Autoimmune polyendocrinopathy syndrome type 1 | AR | |
IL2RA | Immunodeficiency 41 with lymphoproliferation and autoimmunity | AR | ||
IPEX-like syndrome | STAT1 | IPEX-like syndrome | AD | |
STAT5B | Growth defect, primary immunodeficiency, and endocrine abnormalities | AR | ||
Insulin resistance syndromes | Congenital generalized lipodystrophy (Seip-Berardinelli syndrome) | AGPAT2 | CGL1-acromegalic features | AR |
BSCL2 | CGL2-cardiomyopathy, polyneuropathy, mental retardation | AR | ||
CAV1 | CGL3-short stature, pulmonary arterial hypertension, and vitamin D resistance | AR | ||
PTRF | CGL4-congenital myopathy, pyloric stenosis, cardiomyopathy, atlantoaxial instability | AR | ||
Partial lipodystrophy | LMNA | FPLD2-fat loss from limbs; fat deposition in face, neck and perineum (Dunnigan variety) | AD | |
PPARG | FPLD3-loss of subcutaneous fat from distal extremities | AD | ||
PLIN1 | FPLD4-loss of subcutaneous fat from extremities | AD | ||
AKT2 | AKT2 linked FPLD-loss of subcutaneous fat from extremities | AD | ||
CIDEC | FPLD5-fat loss of lower limbs and abdomen, and multilocular lipid droplets | AR | ||
LIPE | FPLD6-upper body pseudo-lipomatosis, fat loss from limbs, and muscle atrophy in some cases | AR | ||
LMNA | Mandibuloacral dysplasia A syndrome-skeletal anomaly, loss of extremity fat, neuropathy, premature ageing | AR | ||
ZMPST24 | Mandibuloacral dysplasia B syndrome-skeletal anomaly, loss of fat, premature renal failure, progeroid | AR | ||
PIK3R1 | SHORT syndrome | AD | ||
POLD1 | MDPL syndrome | De novo | ||
WRN | Werner syndrome-progeria and cataract | AR |
- Citation: Bhattacharya S, Fernandez CJ, Kamrul-Hasan ABM, Pappachan JM. Monogenic diabetes: An evidence-based clinical approach. World J Diabetes 2025; 16(5): 104787
- URL: https://www.wjgnet.com/1948-9358/full/v16/i5/104787.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i5.104787